The global severe asthma drugs market size is estimated to reach USD 26.05 Billion in 2025. It is forecasted to reach a valuation of USD 39.95 Billion by 2032, by exhibiting a CAGR of 6.3% throughout the forecast period (2025-2032). 

Severe asthma and its types are persistent in individuals despite the intake of high-dose corticosteroids and are distinct from poorly controlled asthma. The market is anticipated to scale over the forecast period owing to a surge in air pollution levels caused by rapid industrialization.

The use of monoclonal antibodies (mAb) for inhibiting pathways that drive inflammation is likely to drive the market growth. But their high prices can limit the market growth.

Key Market Insights

The severe asthma drugs market is expected to be marked by non-invasive biomarkers for asthma diagnosis and clinical trials of novel mAbs.

• By current therapies, the biologic therapies segment can account for 20.8% market share in 2025. This can be attributed to the use of mAbs for controlling lung inflammation and adopting a proactive approach to asthma management.
• By biologic therapies, TSLP inhibitors are expected to account for 25% of the market in 2025. Tezepelumab leads in this segment by targeting upstream epithelial cytokines. The reduction in hospitalizations and annualized exacerbations can drive its use over the forecast period.
• By mode of administration, the injections segment can account for a smaller market share in 2025. However, the approval of self-administered injections, coupled with reduced reliance on clinics for subcutaneous administration, can drive the segment growth in the market.
• By application, the pediatric segment can account for a significant market share in 2025. The approvals of drugs such as benralizumab, dupilumab, and omalizumab, along with the prescribed dosing rates for children in schools, can drive the segment growth over the forecast period.
• By geography, the North America region is expected to dominate the severe asthma drugs market over the forecast period. The high penetration of biologics as a line of treatment, combined with the coverage of these drugs by insurance providers, can drive the demand in the region.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/severe-asthma-drugs-market

Severe Asthma Drugs Market Report Coverage

Report Coverage	Details
Market Revenue in 2025	USD 26.05 Billion
Estimated Value by 2032	USD 39.95 Billion
Growth Rate	6.3%
Historical Data	2020–2024
Forecast Period	2025–2032
Forecast Units	Value (USD billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Current Therapies, Biologic Therapies, Mode of Administration, and Application
Geographies Covered	North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa)
Growth Drivers	Rising Prevalence of Severe Asthma Due to Increasing Environmental Pollutants Growing Advancements in Biologics and Monoclonal Antibodies for Personalized Treatments
Opportunities	Emerging Therapies Targeting Novel Cytokines and Inflammation Pathways, such as TSLP and IL-5 Expanding Clinical Trials for Drugs in Phase III and II to Reach Underserved Populations
Trends	Non-invasive Biomarkers Bronchodilator Delivery Masks
Restraints & Challenges	High Cost of Treatment, Especially with Biologic Therapies Lack of Proper Diagnosis and Management in Many Regions, Leading to Undetected Cases

Market Dynamics

The leaps in lung health research for the treatment of respiratory diseases can have a positive impact on the severe asthma drugs market. The repurposing of benralizumab, also known as Fasenra, administered at the point of exacerbation, can be used in the management of the disease. A study published in January 2025 in the Lancet Respiratory Medicine, outlined its advantage over steroids in the treatment of lung inflammation.

Clinical trials on bronchodilator delivery devices and drugs are likely to pave the way for increased funding in the market. The results of a recent study presented at the European Academy of Paediatrics highlighted the promise of the SOBIstat-F device, a delivery mask. The mask proved to reduce the hospitalization rates among candidates and better oxygenation.

Market Opportunity

Bronchodilator Delivery Mask to Improve Outcomes in Pediatric Patients

As per a recent report by the Centers for Disease Control & Prevention (CDC), children accounted for 6.5% of asthma globally. The need for preventive measures for the management of severe asthma among children and alleviating their burden can be a lucrative opportunity for the severe asthma drugs market.

A combination therapy comprising formoterol and budesonide can relieve inflammation in children between the ages of 5-15. The clinical trial was led by the Medical Research Institute of New Zealand (MRINZ), in collaboration with the University of Auckland, Imperial College London, University of Otago, and Starship Children’s Hospital.

Market Challenges

Limited Insurance Coverage

The limited insurance coverage for drugs used in the treatment of severe asthma can significantly limit the market growth. This is despite the strong demand for biologics. For instance, BlueCross BlueShield rolled out a new policy on February 04, 2025, limiting access to asthma infusion treatment within office premises. The drugs — Tezspire, Fasenra, Nucala, and Xolair, can only be administered at home in the U.S. states of Oklahoma, New Mexico, Montana, Texas, and Illinois. This can culminate in a drop in patient adherence to medications and negatively affect the severe asthma drugs market.

Analyst’s View

• The development of biologics and targeted therapies for treating severe asthma is expected to drive market growth over the forecast period.
• The biologic therapies segment is expected to thrive in the market in 2025, due to its efficacy in asthma management.
• Key players are focused on partnerships and acquisitions to lead the charge in novel drug development. 

Recent Developments

Kinaset Therapeutics gained clearance from the U.S. Food and Drug Administration for frevecitinib, an inhaled dry powder, on January 29, 2025.

Competitor Insights

• AstraZeneca
• Novartis
• Biosion
• Amgen,
• Merck & Co. Inc
• Sanofi
• Bio-Thera Solutions
• Johnson & Johnson
• GlaxoSmithKline (GSK)

Market Segmentation

• By Current Therapies
• Inhaled Corticosteroids
• Biologic Therapies
• Bronchodilators
• By Biologic Therapies
• IL-5 Inhibitors
• TSLP Inhibitors
• Cytokine Inhibitors
• By Mode of Administration
• Tablets and Capsules
• Liquid Inhalers
• Injections
• By Application
• Pediatric
• Adults

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa